Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Ovarian Cancer Advanced 2026

Charlie Gourley

查理·高利

MBChB, PhD, FRCP

🏢University of Edinburgh / Edinburgh Cancer Research(爱丁堡大学/爱丁堡癌症研究中心)🌐UK

Chair in Oncology; Honorary Consultant Medical Oncologist肿瘤学讲席教授;荣誉顾问肿瘤内科医生

51
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Charlie Gourley is Chair in Oncology at the University of Edinburgh and one of the UK's foremost experts on BRCA-related ovarian cancer and PARP inhibitor biology. He has led seminal translational research into mechanisms of HRD and PARP inhibitor resistance, and was a key investigator in early olaparib trials. His work has clarified the biology of BRCA-deficient ovarian tumors and mechanisms underpinning sensitivity and acquired resistance to PARP inhibition.

Share:

🧪Research Fields 研究领域

Olaparib BRCA Ovarian Cancer奥拉帕尼BRCA卵巢癌
PARP Inhibitor Clinical TrialsPARP抑制剂临床试验
Homologous Recombination Deficiency同源重组缺陷
BRCA1/2 MutationsBRCA1/2突变
Platinum-Sensitive Recurrence铂敏感复发
Ovarian Cancer Biology卵巢癌生物学

🎓Key Contributions 主要贡献

BRCA and HRD Biology in PARP Inhibitor Response

Led translational studies defining the molecular basis of PARP inhibitor sensitivity and resistance in BRCA-mutant and HRD ovarian cancers, including reversion mutations as acquired resistance mechanisms, published in high-impact journals.

Early-Phase Olaparib Trials in Ovarian Cancer

Key investigator in early clinical development of olaparib in BRCA-mutant ovarian cancer, contributing to pivotal data supporting regulatory approval of the first PARP inhibitor in this setting.

Representative Works 代表性著作

[1]

BRCA1/2 Reversion Mutations in Platinum-Resistant Ovarian Cancer Confer Cross-Resistance to PARP Inhibitors

Journal of Clinical Oncology (2017)

Demonstrated that BRCA reversion mutations are a major mechanism of acquired resistance to PARP inhibitors and platinum therapy in ovarian cancer.

[2]

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer (Study 19)

New England Journal of Medicine (2012)

Phase II trial establishing proof-of-concept for olaparib maintenance in platinum-sensitive relapsed BRCA-mutant ovarian cancer, foundational for subsequent approvals.

🏆Awards & Recognition 奖项与荣誉

🏆Cancer Research UK Senior Cancer Research Fellowship
🏆Scottish Government Chief Scientist Office Award
🏆ESGO Scientific Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 查理·高利 的研究动态

Follow Charlie Gourley's research updates

留下邮箱,当我们发布与 Charlie Gourley(University of Edinburgh / Edinburgh Cancer Research)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment